Botanix Pharmaceuticals (ASX:BOT) – Presentation to Botanix Advisory Board, page-11

Referring to slide 5,  OVERVIEW Novel approach (bullet point)

Lead products based on synthetic form of a widely studied natural product which greatly enhances the probability of clinical and regulatory success ​

This statement is false and misleading. It is pure spin. Having a lead product based on the synthetic form of a widely studied natural product may greatly enhance BOT's CONFIDENCE in the probability of clinical and regulatory success but not probability of success as claimed. BOT claims its compound is a novel approach of its novel lead products. It still has to jump through the same hoops as every other product on its path to regulatory approval. The only shortcut available is, say, with the FDA by gaining Orphan Drug status pathway approval.